Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoglu, Ibrahim; Kucukzeybek, Betul; Kucukzeybek, Yuksel; Varol, Umut; Yildiz, Ibrahim; Alacacioglu, Ahmet; Akyol, Murat; Demir, LÜTFİYE; Dirican, Ahmet; Yildiz, Yasar; Salman, Tarik; Tarhan, Mustafa

doi:10.1016/j.biopha.2015.01.019

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz I., Alacacioglu A., ...Daha Fazla

BIOMEDICINE & PHARMACOTHERAPY, cilt.70, ss.190-195, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 70
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.biopha.2015.01.019
Dergi Adı: BIOMEDICINE & PHARMACOTHERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.190-195
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Purpose: Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-kappa B/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis.